Randomized controlled trial to compare CMV antigenemia assay and real-time PCR after unrelated bone marrow transplantation.

Randomized controlled trial to compare CMV antigenemia assay and real-time PCR after unrelated bone marrow transplantation. - Comparison between CMV antigenemia assay and real-time PCR.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000347

Enrollment

100

Registered

2006-03-10

Start date

2001-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone marrow transplant recipients.

Interventions

pre-emptive therapy based on antigenemia assay pre-emptive therapy based on real-time PCR

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hematological malignancies Use of conventional conditioning regimen. Transplantation from a serologically HLA-matched unrelated donor.

Exclusion criteria

Exclusion criteria: Life expectancy shorter than 3 months Both donor and recipient CMV negative Severe organ dysfunction or infection ECOG PS 2-4

Design outcomes

Primary

Measure	Time frame
Incidence of CMV disease within 100 days after transplantation	—

Countries

Japan

Contacts

Public ContactYoshinobu Kanda

University of Tokyo Hospital Department of Hematology & Oncology

ycanda-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026